18 Despite the success of Vaccinia virus (VACV) against smallpox there remains a paucity of 19 information on Dendritic cell (DC) responses to the virus, especially on the traffic of DCs and 20 VACV to draining LN (dLN). Herein we studied skin DC migration in response to VACV and 21 compared it to the tuberculosis vaccine Mycobacterium bovis Bacille Calmette-Guérin (BCG), 22 another live-attenuated vaccine administered via the skin. In stark contrast to BCG, skin DCs 23 did not relocate to dLN in response to VACV. This happened in spite of virus-induced 24 accumulation of several other innate-immune cell populations in the dLN. UV inactivation of 25 VACV or use of the Modified Vaccinia virus Ankara (MVA) strain promoted DC movement 26 to dLN, indicating that the virus actively interferes with skin DC migration. This active immune 27 suppression by VACV was potent enough to ablate the mobilization of skin DCs in response to 28 BCG, and to reduce the transport of BCG to dLN. Expression of inflammatory mediators 29 associated with BCG-triggered DC migration were absent from virus-injected skin, suggesting 30 that other pathways provoke DC movement in response to replication-deficient VACV. Despite 31 viral suppression of DC migration, VACV was detected in dLN much earlier than BCG, 32 indicating a rapid, alternative route of viral traffic to dLN despite marked blockade of skin DC 33 mobilization from the site of infection. 34 35 Word count: 217 36 37
Introduction

38
Dendritic cells (DCs) excel in their capacity to capture, transport and present microbial antigen 39 to prime naïve T cells in secondary lymphoid organs (1). The lymph node (LN) is a major site 40 for such antigen presentation which is often preceded by the relocation of DCs from the site of 41 infection in the periphery to the draining LN (dLN) (2). Despite a large body of data on 42 immunizations with model antigens, DC migration remains incompletely understood during 43 infection with pathogens and live-attenuated bacterial or viral vaccines. Using an infection 44 model in mice and a novel assay to track DC migration in vivo, we have previously identified 45 a role for interleukin-1 receptor (IL-1R) signaling in mobilizing a sub-population of skin DCs 46 to dLN in response to Mycobacterium bovis Bacille Calmette-Guérin (BCG), the live-47 attenuated tuberculosis (TB) vaccine (3). In particular, we found the population of migratory 48 CD11b high EpCAM low skin DCs to be engaged in BCG transport from its inoculation site in the 49 skin to dLN and in doing so, to prime mycobacteria-specific CD4+ T cells in the dLN (3). 50
Like BCG, the smallpox vaccine Vaccinia virus (VACV) is a live-attenuated 51 microorganism administered via the skin. Despite many studies on the immune response to 52 poxviruses and countless investigations on anti-viral T-cell priming, there is a knowledge gap 53 on the initial events that unfold in vivo in response to VACV. Due to its large genome and 54 replication-cycle features, VACV is readily used as an expression vector and live-recombinant 55 vaccine for infectious diseases and cancer (4-7). Since BCG efficacy is sub-optimal, there is a 56 standing need to improve TB vaccination. Both improved BCG as well as novel vaccine 57 candidates are considered or have been developed, some of which are currently undergoing 58 clinical trials. In the context of VACV vectors, Modified Vaccinia virus Ankara (MVA) 59 expressing the major M. tuberculosis antigen 85A (MVA85A) is an example of a clinically-60 advanced vaccine candidate (8) . 61
Following inoculation of VACV in the skin, infected cells including LN DCs and 62 macrophages (9) can be detected in the dLN within a few hours (9-12). It is not entirely clear 63 how this rapid relocation of virus from skin to dLN occurs, e.g. if through direct viral access to 64 lymphatic vessels or supported through other mechanisms. Similar observations have been 65 reported after skin infection with Zika virus (12) and Semliki Forest virus (13) . In contrast, 66 other studies indicate that VACV is largely restricted to its inoculation site in the skin with 67 limited or null relocation of virus to dLN (14, 15) . In this regard, VACV has been shown to 68 interfere with fluid transport in lymphatic vessels and as such to curb its dissemination (16) . In 69 addition to data on viral traffic to dLN, there is substantive literature on immunomodulatory 70 molecules produced by VACV and on the overall immunosuppressive properties of VACV 71 infection in vitro and in mouse models (17). Using an established toolset for investigating DC 72 responses to mycobacteria, we herein compared local BCG-triggered, inflammatory responses 73 in the skin and skin dLN to that of VACV, especially the ability of VACV to mobilize skin DCs 74 into dLN. We found that unlike the early reaction to BCG, VACV actively inhibits skin DC 75 migration to dLN while retaining the capacity to relocate to dLN in the absence of DC transport. 76 77
Materials and Methods
78
Mice 79 C57BL/6NRj mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France) and used 80 as wild-type (WT) controls. P25 TCRTg RAG-1 -/mice expressing EGFP (18) at an amount equivalent to 1x10 6 PFUs before UV-inactivation. Control animals received 30 µL 111 of PBS only. For footpad conditioning experiments, animals were injected in the footpad with 112 PBS, VACV or i-VACV 24 hrs before receiving BCG into the same footpad. For studying gene 113 expression in the skin, mice were inoculated in the ear dermis with 5 µL PBS containing the 114 same concentration of mycobacteria or virus as above. Control animals received 5 µL PBS. 115
Assessment of cell migration from the footpad skin to dLN was done as previously 116 described (3, 24) . Briefly, animals previously injected with vaccine or PBS where injected 24 117 hrs before sacrifice in the same footpad with 30 µL of 0.5 mM 5-and 6-carboxyfluorescein 118 diacetate succinimidyl ester (CFSE) (Invitrogen). For assessing migration after 24 hrs, CFSE 119 was injected 2 hrs after vaccine or PBS inoculation. For studying CD4+ antigen-specific T-cell 120 responses, 1x10 5 LN cells from naïve P25 TCRTg RAG-1 -/-EGFP mice were injected i.v. in 121 the tail vein of C57BL/6 recipients in a final volume of 200 µL. Recipients were infected 24 122 hrs later in the footpad with 30 µL of BCG or virus. Control animals received PBS. In footpad 123 conditioning experiments, recipients received naïve T cells as above and were injected in the 124 footpad 2 hrs later with PBS, VACV or i-VACV. BCG was given the next day and animals 125 sacrificed 6 days after BCG. 126 127
Generation of single-cell suspensions from tissue 128
Popliteal LNs (pLNs) were aseptically removed, transferred to microcentrifuge tubes 129 containing FACS buffer (5 mM EDTA and 2% FBS in PBS) and gently homogenized using a 130 tissue grinder. The resulting single-cell suspension was counted by Trypan blue exclusion. In 131 certain experiments, an aliquot was taken and subjected to CFU or PFU determinations as 132 
Statistical analyses 156
Analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc., USA). One-way 157
Anova with Tukey's multiple comparison test was used to compare data group means with a 158 cut-off of p <0.05 considered significant. 159 160
Results
161
Skin DCs migrate to dLN in response to BCG but not VACV 162
To begin investigating the early events after VACV infection, we inoculated C57BL/6 wild-163 type mice in the footpad skin and assessed immune responses in the draining, popliteal LN 164 (pLN). A CFSE fluorochrome-based migration assay was used to track the movement of 165 migratory skin DCs to dLN. (3, 24) . We have used this setup in the past to study early responses 166 to BCG, another live-attenuated vaccine and so included BCG as a comparison to VACV. 167
Corroborating our previous results, BCG skin infection triggered migration of skin DCs to dLN. 168
However, in stark contrast to BCG, skin DCs did not relocate to dLN in response to VACV 169 ( Fig. 1A-C ). The lack of DC movement in response to VACV was independent of viral 170 inoculation dose ( Fig. 1A ) and the timepoint in which DC migration was investigated ( Fig. 1B) . 171
The absence of CFSE-labeled (i.e. migratory) skin DCs in the dLN of VACV-infected mice 172 was not concurrent with CFSE labeling in other immune-cell populations, suggesting a 173 generalized absence of cells moving to dLN in response to VACV (Fig. 1C) . 174
Although migratory skin DCs did not readily relocate to dLN in response to VACV, 175 virus infection provoked a robust inflammatory response in the dLN, with an increase in LN 176 cell numbers ( Fig. 2A ) accompanied by the expansion of several innate immune-cell 177 populations and especially CD64 high Ly6G low cells (Fig. 2B ). The lack of skin DC migration 178 recorded in our CFSE-based migration assay was also in line with a marked decrease in the 179 overall number of migratory skin DCs (MHC-II high CD11c +/low cells) in VACV-infected LN, 180 suggesting that skin DCs may be a particular target of VACV immunosuppression. 181
182
VACV actively inhibits skin DC migration to dLN 183
Since many of the known immunomodulatory molecules produced by VACV require viral 184 replication, we investigated if the absence of DC migration in response to VACV was coupled 185 to productive infection. We exposed VACV to UV cross-linking at levels sufficient to ablate 186 viral replication but without abolishing viral entry into cells (25). Interestingly, inoculation of 187 UV-inactivated VACV (i-VACV) in the footpad promoted robust skin DC mobilization to dLN 188 ( Fig. 3A) . Similarly, skin infection with MVA, a highly-attenuated VACV that infects but fails 189 to assemble new virions in mammalian cells (26), also triggered DC migration to dLN (Fig. 190 3A) . Results with i-VACV and MVA thus indicate that live, replication-competent VACV is 191 actively blocking skin DC migration. Moreover, EpCAM low CD11b high DCs were found to be 192 the main DC sub-population contributing to migration in response to i-VACV and MVA (Fig. 193 3B), an observation similar to BCG ( Fig. 3B) (3, 27). 194 Consistent with a potent suppressive effect on skin DC migration, conditioning the 195 footpad with VACV prior to injecting BCG in the same footpad completely blocked skin DC 196 migration to BCG (Fig. 4A ). The absence of skin DCs entering the dLN was also associated 197 with a massive drop in BCG levels in the dLN (Fig. 4B ), in line with the fact that these DCs 198 transport BCG to dLN (3). Interestingly, DC migration was not impaired when conditioning 199 was done with i-VACV or MVA ( Fig. 4A and data not shown). The number of moving DCs 200 was rather increased (Fig. 4A) , although BCG entry itself was slightly lower in the i-VACV-201 conditioned group compared to PBS-conditioned controls (Fig. 4B) Although DC migration was blocked in response to VACV, the virus was detected in the dLN 219 as early as 10 min after infection in the footpad skin and levels remained steady over time (Fig.  220   6A) . The kinetics of this response was different and notably faster than BCG entry into dLN 221 ( Fig 6B) , which is known to be reliant on DC transport (3), suggesting an alternative pathway 222 for VACV entry to dLN. 223 224 Discussion 225 VACV is a live-attenuated vaccine that infects a variety of cell types in the skin, including 226 keratinocytes, epidermal and dermal DCs (28). The virus is intriguing in that it packs a diverse 227 immunosuppressive arsenal while still being highly immunogenic. Concurrent with this 228 complexity, the outcome of DC-VACV interactions remains incompletely understood. The fate 229 of the virus and its transport to dLN for antigen presentation is another matter of interest given 230 that VACV is recognized as a vaccine vector and tool for antigen delivery. We show that VACV 231 profoundly inhibits the ability of skin DCs to mobilize to dLN. This inhibition was dependent 232 on viral replication and capable of dampening DC migration to a subsequent challenge with 233 BCG. VACV could nevertheless relocate to dLN in the absence of DC mobilization. Our study 234 supports recent observations that LN conduits transport VACV to dLN for T-cell priming (12). 235
We also add to a large body of data on the immunosuppressive properties of VACV (17) and 236 extend these to include virus-mediated inhibition of DC migration. 237 VACV infection is known to have many negative effects on DC function. For instance, 238 the virus can inhibit expression of DC costimulatory molecules and cytokines (29-31). Further, 239 splenic DCs isolated from VACV-infected mice have lower MHC-II levels and antigen-240 presentation capacity (32). We also report lower expression of MHC-II on migratory skin DCs 241 from the dLN of VACV-infected mice ( Supplementary Fig. 1A ). VACV undergoes abortive 242 replication in DCs (29-31, 33) but VACV and MVA can induce apoptosis in DCs (32). 243
Although we did not assess virus-induced DC death in our studies, the frequency of migratory 244 skin DCs in the dLN of VACV-infected mice was lower than for BCG but similar to that of 245 PBS-injected controls ( Supplementary Fig. 1B ). This speaks against DC death in the skin, 246 which would lower the pool of migratory DCs in skin and consequently, the frequency of these 247 DCs in the dLN. Results from our migration assay point instead to an impediment of skin DC 248 traffic to dLN during VACV infection. 249
We also observed muted influx of skin DCs and BCG into dLN if the injection site in 250 the footpad skin had been pre-conditioned with VACV. Thus, the suppressive effect of VACV 251 on DC migration was robust enough to interfere with DC movement triggered by a secondary 252 stimulus (BCG). Interestingly, conditioning with i-VACV doubled the number of migratory 253 skin DCs reaching the dLN without enhancing the entry of BCG. Conditioning with inactivated 254 virus may have reduced skin DC pools available for BCG transport in the next step. 255
Enhanced expression of TNF-a and IL-1 in the skin was associated with BCG-but not 256 virus-triggered skin DC migration. Migration induced by iVACV and MVA thus highlight an 257 alternative mechanism for EpCAM low CD11b high DCs to move to dLN. Indeed, the contribution 258 of IL-1R signaling in response to BCG is also partial (3) so there must be other factors 259 regulating migration. Similarly, infection with VACV deletion mutants ΔA49, ΔB13 and ΔB15, 260 lacking molecules that inhibit NF-ĸB, Caspase-1 and IL-1 respectively, was not able to provoke 261 DC influx to dLN ( Supplementary Fig. 2) . During M. tuberculosis infection, IFN-a/b has been 262 shown to block IL-1 production from myeloid cells (34). Whether the lack of IL-1 expression 263 in VACV-infected skin or VACV inhibition of skin DC migration is coupled to IFN-a/b 264 remains to be determined. Evaluating cytokine expression and DC migration in IFN-a/bR -/-265 mice may help clarify this point. 266
Although VACV did not induce expression of pro-inflammatory cytokines in the skin, 267 it did leash a profound inflammatory infiltrate in the dLN. CD169+ subcapsular sinus (SCS) 268 macrophages are directly exposed to afferent lymph-borne particulates and thus form a strategic 269 line of defense in the dLN against free-flowing viruses, including VACV, preventing their 270 systemic spread (35) . Previous studies confirm VACV infection of SCS macrophages (9, 36) . can reach the dLN without mobilizing skin DCs, whose migration is blocked by the virus. We 282 speculate that skin DC-independent mechanism of virus relocation occurs via direct access of 283 VACV to lymphatic vessels. Previous studies show VACV in dLN within a few hours after 284 injection in the skin (9-12). We report the virus in the pLN even earlier, just a few minutes after 285 PFUs), UV-inactivated VACV (i-VACV, equivalent to 10 6 PFUs before UV treatment) or 342 MVA (10 6 FFUs) and subjected to CFSE migration assay as in Fig. 1. pLN 
